We often receive questions from ketamine clinics regarding who must obtain a DEA registration to dispense controlled substances. There are two candidates to consider – the healthcare providers who work at the clinic and the clinic itself. Often, there is a misconception about whether a clinic needs to hold a DEA registration. We wrote about
Welcome to the fourth installment in this series surveying business and regulatory issues in the Oregon psilocybin program. Today I’ll cover access to professional service providers. Service Providers and the Oregon Psilocybin Industry I’ve mentioned before that Oregon psilocybin shares many parallels with what came before with cannabis. In the early days of cannabis, it
The gap in the treatment of controlled substances between the state and federal levels continues to widen. That has long been true with cannabis, but the trend has accelerated with psilocybin and other psychedelics recently. This growing disparity has implications under U.S. immigration law for employers and non-residents who wish to become involved in the
We’ve been taking early calls on Oregon psilocybin for over a year, going back to when Measure 109 passed. I’m always happy to talk to people, but there simply isn’t much to do yet. Currently, the Oregon Psilocybin Advisory Board (“Board”) and its subcommittees are meeting to formulate recommendations on program rules. Eventually draft rules
We often receive calls from potential ketamine clinic clients that just signed a letter of intent (“LOI”) or term sheet to acquire entire medical practices that are undertaking ketamine treatments. In the psychedelics space, many companies are starting off with off-label ketamine treatments while building towards a bigger suite of psychedelic services as the laws
